Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 17.
doi: 10.1681/ASN.0000000766. Online ahead of print.

Use of eGFR Slope Thresholds as End Point Components in a Kidney Disease Progression Hierarchical Composite End Point

Niels Jongs  1 , Samvel B Gasparyan  2 , Lars Frison  3 , Patrick Schloemer  4 , Meike Brinker  5 , Dustin J Little  6 , Hiddo J L Heerspink  1   7
Affiliations

Use of eGFR Slope Thresholds as End Point Components in a Kidney Disease Progression Hierarchical Composite End Point

Niels Jongs et al. J Am Soc Nephrol. .
No abstract available

Keywords: CKD; GFR; SGLT2; angiotensin; clinical trial; epidemiologic methods; epidemiology and outcomes; kidney disease; nephrology; outcomes.

PubMed Disclaimer

References

    1. Heerspink HJL, Schloemer P, Jongs N, et al. Development and validation of a new hierarchical composite end point for clinical trials of kidney disease progression. J Am Soc Nephrol. 2023;34(12):2025–2038. doi: 10.1681/ASN.0000000000000243 - DOI
    1. Little DJ, Schloemer P, Gasparyan SB, et al. Validity and utility of a hierarchical composite end point for clinical trials of kidney disease progression: a review. J Am Soc Nephrol. 2023;34(12):1928–1935. doi: 10.1681/ASN.0000000000000244 - DOI
    1. Inker LA, Collier W, Greene T, et al. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nat Med. 2023;29(7):1867–1876. doi: 10.1038/s41591-023-02418-0 - DOI
    1. Buyse M. Generalized pairwise comparisons of prioritized outcomes in the two-sample problem. Stat Med. 2010;29(30):3245–3257. doi: 10.1002/sim.3923 - DOI
    1. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. New Engl J Med. 2020;383(15):1436–1446. doi: 10.1056/NEJMoa2024816 - DOI

Associated data

LinkOut - more resources